Based on these clinical circumstances, silymarin and frondoside A targeting PG-activated EP receptor signaling can be used as substitutes of COX-2 inhibitors in cancer therapies to reduce side effects and improve therapeutic efficacies. This evidence concerns the gene PTGS2 and cancer.